Algos Therapeutics is pursuing novel developments in the treatment of chronic pain while providing contract behavioral research services related to pain. The Company's foundation is built upon promising intellectual property and a unique, focused set of scientific capabilities. An exceptionally strong intellectual property portfolio is the basis for internal drug discovery research and development program, providing a unique understanding of the causes and potential treatment strategies for chronic pain states.

Algos' specialized behavioral models mimic chronic pain states in humans and serve as powerful tools for evaluating drug candidates. The Company offers quality research services to facilitate discovery and development of analgesics according to the goals of pharmaceutical and biotechnology clients.

As Quatris' most recent investment, Algos represents our first foray into the biotech market. Securing its first NIH grant soon after our investment, the Company has hit the ground running, with steady progress in setting up its internal research initiatives and in pursuit of contract research customers.

CEO: Susanne Dvorak

Susanne Dvorak has spent the last 17 years as a technology-based business development and finance professional. Most recently, she was the senior business leader at Neuromics, Inc., after having spent eight years at Cargill managing new bioscience- and technology-based initiatives. She established her career by building a solid foundation in finance, serving as Director of Capital Markets at Northwest Airlines, Manager of International Structuring for Security Pacific Bank in San Francisco, and Financial Analyst for Associates National Bank in Pleasanton, California.

Chief Scientific Officer & COO: Todd A. Verdoorn

Dr. Todd Verdoorn has led research efforts in both academic and industrial environments for over 14 years. Most recently, Dr. Verdoorn held senior leadership positions at Bristol Myers Squibb (BMS) Pharmaceutical Research Institute, where he led a number of drug development projects for neurological disorders. He brings a strong scientific record and a clear vision for discovering new treatments for pain.

Prior to BMS, Dr. Verdoorn taught in the Department of Pharmacology at Vanderbilt University School of Medicine. He completed a postdoctoral research fellowship at the Max-Planck-Institute with Dr. Bert Sakmann, who was later awarded the Nobel Prize. Dr. Verdoorn earned his Ph.D. in Neurobiology from the University of North Carolina. Dr. Verdoorn has authored over 35 original research articles and book chapters including four papers published in Science. He also has received 17 awards and grants.

www.algosinc.com